- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
FibroBiologics Completes Manufacturing of Diabetic Foot Ulcer Drug
The CYWC628 fibroblast-based therapy will enter first-in-human clinical trials in 2026.
Mar. 31, 2026 at 9:53pm
Got story updates? Submit your updates here. ›
FibroBiologics, a clinical-stage biotechnology company, announced the successful completion of manufacturing the first batch of its proprietary CYWC628 drug product that will support upcoming first-in-human clinical trials for the treatment of diabetic foot ulcers. The drug product was manufactured in accordance with FDA Good Manufacturing Practices.
Why it matters
Diabetic foot ulcers are a serious condition that affects millions of patients worldwide and currently lacks effective long-term treatment solutions. The successful manufacturing of CYWC628, the first fibroblast-based spheroid therapeutic candidate, represents a significant milestone in FibroBiologics' efforts to develop new treatments for chronic diseases using fibroblast cells and materials.
The details
The CYWC628 fibroblast-based therapy targets diabetic foot ulcers, a condition that affects millions of patients worldwide and currently lacks effective long-term treatment solutions. FibroBiologics' Founder and CEO, Pete O'Heeron, stated that 'CYWC628 is not only the first fibroblast-based spheroid therapeutic candidate, its manufacture also represents the first large-scale CGMP manufacturing of a spheroid product for therapeutic use.' These achievements by the company's scientific team will allow them to move forward with a planned Phase 1/2 clinical trial utilizing CYWC628 in DFU patients in the first half of 2026.
- FibroBiologics announced the successful completion of manufacturing the first batch of CYWC628 drug product on March 31, 2026.
- The company plans to initiate a Phase 1/2 clinical trial utilizing CYWC628 in diabetic foot ulcer patients in the first half of 2026.
The players
FibroBiologics, Inc.
A clinical-stage biotechnology company with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials.
Pete O'Heeron
Founder and Chief Executive Officer of FibroBiologics.
What they’re saying
“CYWC628 is not only the first fibroblast-based spheroid therapeutic candidate, its manufacture also represents the first large-scale CGMP manufacturing of a spheroid product for therapeutic use.”
— Pete O'Heeron, Founder & Chief Executive Officer of FibroBiologics
What’s next
FibroBiologics plans to initiate a Phase 1/2 clinical trial utilizing CYWC628 in diabetic foot ulcer patients in the first half of 2026.
The takeaway
The successful manufacturing of FibroBiologics' CYWC628 drug product, the first fibroblast-based spheroid therapeutic candidate, represents a significant milestone in the company's efforts to develop new treatments for chronic diseases using innovative cell-based therapies.
